Chair Lawrence Schiller, MD, FACP, FACG Professor of Medicine Texas A&M College of Medicine Baylor University Medical Center Campus Dallas, TX
Faculty Brian Lacy, MD, PhD Section Chief Gastroenterology and Hepatology Professor of Medicine Geisel School of Medicine, Dartmouth Dartmouth-Hitchcock Medical Center Lebanon, NH
Brooks Cash, MD, FACP, FACG Professor of Medicine Division of Gastroenterology University of South Alabama Mobile, AL
AMA PRA Category 1 Credit TM Medium
Constipation-predominant irritable bowel syndrome (IBS-C) is a subtype of IBS that comprises approximately 20% of IBS cases and is associated with poor health-related quality of life. Chronic constipation (CC) affects approximately 15% of US adults (with a prevalence as high as 34% in older adults) and is associated with a similarly negative impact on quality of life. Adequate treatment of IBS-C and CC is fraught with challenges. The heterogeneous, multisymptomatic nature of these conditions necessitates a patient-centric model of care involving extensive knowledge of IBS-C and CC pathophysiology and treatment options, as well as an optimized patient-clinician relationship, for best outcomes. We have identified several gaps in knowledge and clinical practice among clinicians, as well as opportunities to improve practice patterns. The goal of this continuing education activity is to enhance competency and build additional skills among internists in the treatment and management of IBS-C and CC, ultimately improving outcomes for those who suffer from these conditions.
. Target Audience
This activity is intended for internal medicine physicians and other primary care clinicians involved in the care of patients with chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C).
Upon completion of this educational activity, the participant should be able to:
Review recent research on both currently understood and novel pathophysiological aspects of IBS-C and CC.
Outline the heterogeneous nature and varying causes of IBS-C and CC pathophysiology and symptomatology that can present in each patient.
Discuss the mechanisms of action and potential side effects of existing agents for the treatment of IBS-C and CC.
Summarize important safety and efficacy data of investigational agents for IBS-C and CC.
Outline strategies for selecting optimal pharmacotherapy to treat the underlying cause and symptoms of IBS-C and CC in each patient.
Describe strategies designed to improve patient-clinician communication and the patient-clinician relationship.
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.
Lawrence Schiller, MD, FACP, FACG has disclosed the following:
Speakers Bureau: AbbVie, Forest Laboratories, Ironwood Pharmaceuticals, Santarus/Salix Pharmaceuticals, and Takeda Pharmaceuticals
Consultant: Janssen Pharmaceuticals
Brian Lacy, MD, PhD has disclosed the following:
Consultant: Ironwood Pharmaceuticals, Prometheus Laboratories, and Takeda Pharmaceuticals
Brooks Cash, MD has disclosed the following:
Speakers Bureau: Forest Laboratories, Ironwood Pharmaceuticals, Salix Pharmaceuticals, and Takeda Pharmaceuticals
Consultant: Forest Laboratories, Ironwood Pharmaceuticals, Salix Pharmaceuticals, and Takeda Pharmaceuticals
Penn State faculty and staff involved in the development and review of this activity have nothing to disclose.
Gena Dolson, MCM Education Senior Medical Writer, has nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit is awarded to participants who score 70% or better on the post-test.
The online activity will take approximately 75 minutes to complete.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G5558-15-T. Commercial Support Statements
Supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region and Sucampo.
There are no fees for participating in or receiving credit for this online educational activity. This activity is designed to be completed within the time designated on this page; physicians should claim only those credits that reflect the time actually spent in the activity.
Review the intended audience, learning objectives, and author disclosures.
Study the educational content online.
Once completed, continue to post-test. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must also complete the Activity Evaluation.
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Penn State College of Medicine, or Takeda Pharmaceuticals International, Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.